Epidemiology and long-term outcome in outpatients with chronic heart failure in Northwestern Europe

Heart
Hanna FröhlichMorten Grundtvig

Abstract

To describe the epidemiology, long-term outcomes and temporal trends in mortality in ambulatory patients with chronic heart failure (HF) with reduced (HFrEF), mid-range (HFmrEF) or preserved ejection fraction (HFpEF) from three European countries. We identified 10 312 patients from the Norwegian HF Registry and the HF registries of the universities of Heidelberg, Germany, and Hull, UK. Patients were classified according to baseline left ventricular ejection fraction (LVEF) and time of enrolment (period 1: 1995-2005 vs period 2: 2006-2015). Predictors of mortality were analysed by use of univariable and multivariable Cox regression analyses. Among 10 312 patients with stable HF, 7080 (68.7%), 2086 (20.2%) and 1146 (11.1%) were classified as having HFrEF, HFmrEF or HFpEF, respectively. A total of 4617 (44.8%) patients were included in period 1, and 5695 (55.2%) patients were included in period 2. Baseline characteristics significantly differed with respect to type of HF and time of enrolment. During a median follow-up of 66 (33-105) months, 5297 patients (51.4%) died. In multivariable analyses, survival was independent of LVEF category (p>0.05), while mortality was lower in period 2 as compared with period 1 (HR 0.81, 95% CI 0.72...Continue Reading

References

Mar 14, 2003·European Heart Journal·M KomajdaUNKNOWN Study Group on Diagnosis of the Working Group on Heart Failure of the European Society of Cardiology
Nov 16, 2004·European Journal of Heart Failure·Fátima CeiaAntónio G Oliveira
Dec 7, 2005·Circulation·Scott D SolomonUNKNOWN Candesartan in Heart Failure Reduction in Mortality (CHARM) Investigators
Nov 9, 2006·JAMA : the Journal of the American Medical Association·Francesca BursiVéronique L Roger
Aug 19, 2007·Heart·Arend Mosterd, Arno W Hoes
Aug 21, 2007·Journal of the American College of Cardiology·Gregg C FonarowUNKNOWN OPTIMIZE-HF Investigators and Hospitals
Jan 17, 2009·European Journal of Heart Failure·Ulf DahlstromAnders Waldenstrom
Mar 27, 2010·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Andrew S Levey, Lesley A Stevens
May 11, 2010·European Journal of Cardiovascular Nursing : Journal of the Working Group on Cardiovascular Nursing of the European Society of Cardiology·Morten GrundtvigArne Westheim
Sep 2, 2010·European Journal of Heart Failure·Aldo P MaggioniUNKNOWN Heart Failure Association of ESC (HFA)
Aug 9, 2011·European Heart Journal·UNKNOWN Meta-analysis Global Group in Chronic Heart Failure (MAGGIC)
Jan 13, 2012·European Journal of Heart Failure·Said LaribiUNKNOWN GREAT network
Sep 25, 2012·The European Journal of General Practice·Maurizio CancianRoberto Toffanin
Mar 12, 2013·Circulation. Heart Failure·Luigi TavazziUNKNOWN IN-HF (Italian Network on Heart Failure) Outcome Investigators
Jan 7, 2014·Archives of Cardiovascular Diseases·Yves JuillièreUNKNOWN ODIN cohort participants
Apr 30, 2014·Revista Española De Cardiología·Eva Frigola-CapellJose M Verdú-Rotellar
Sep 12, 2014·European Journal of Heart Failure·Carolyn S P Lam, Scott D Solomon
Jul 14, 2017·Frontiers in Microbiology·Liselot DewachterJan Michiels
Nov 17, 2017·Journal of the American College of Cardiology·Kevin S ShahGregg C Fonarow

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.